Clinical Trial Update: Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tucatinib plus trastuzumab with oxaliplatin-based chemotherapy or pembrolizumab-containing regimens for HER2-positive gastrointestinal …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Colorectal Cancer
• Esophageal Adenocarcinoma
• Gallbladder Cancer
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Eloxatin (oxaliplatin)
• HERCEPTIN (trastuzumab)
• KEYTRUDA (PEMBROLIZUMAB)
• Tukysa (tucatinib)

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: Colorectal Carcinoma, Gastric Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-09-09